<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-84504</identifier>
<setSpec>0214-6266</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Importance of cyclooxigenase-2 polymorphismsin the clinical presentation of sarcoidosis</dc:title>
<dc:description xml:lang="en">OBJECTIVE: To study clinical manifestations of sarcoidosis according to cyclooxigenase-2 (COX-2) polymorphisms. METHOD: Observational cross-sectional multicentre trial in which 7 Spanish hospitals participated. Patients diagnosed withs arcoidosis according to international criteria were included. Age, gender, diagnostic method, angiontens in converting enzyme, pulmonary function tests, radiological stage and clinical findings at the moment of the diagnosis were recorded for each case included. Clinical findings were grouped as respiratory or systemic. Genetic studies were performed on DNA extracted from peripheral blood lymphocytes. DNA was amplified by conventional PCR and polymorphisms were studied by Fluorescent Hybridization Probe-Melting Curves. COX-2 polymorphisms genotyped were COX2.5909T&gt;G, COX2.8473 T&gt;C, COX2.926 G&gt;C y COX2.3050 G&gt;C.RESULTS: 131 sarcoidosis patients (63 males, age: 47 ± 15years) were included. All included patients had a histological diagnosis except for 5 patients. COX2.3050G&gt;C homozygote polymorphism resulted to be significantly present in patients with a systemic manifestation of the disease as compared with the rest of the sample(4,6% vs 0%; p = 0,045). Systemic manifestations were significantly associated with allele C carriers of this polymorphism (34.4% vs.18.6%; p = 0.031; OR: 2.3; IC 95%: 1.03 &#150; 5.12). The rest of the studied polymorphisms were not significantly related to the clinical manifestations of the disease. CONCLUSION: Our results suggest that allele C carriers ofCOX2.3050G&gt;C polymorphism are associated with the systemic manifestations of sarcoidosis (AU)</dc:description>
<dc:creator>Montes-Worboys, A</dc:creator>
<dc:creator>Rodríguez-Becerra, E</dc:creator>
<dc:creator>Alfageme Michavila, I</dc:creator>
<dc:creator>Casanova, A</dc:creator>
<dc:creator>López-Campos, J. L</dc:creator>
<dc:creator>García Hernández, F. J</dc:creator>
<dc:creator>Arellano-Orden, E</dc:creator>
<dc:creator>Fernández Guerra, J</dc:creator>
<dc:creator>Romero Ortiz, A</dc:creator>
<dc:creator>Fernández de Córdoba Gamero, J</dc:creator>
<dc:creator>Rodríguez-Rodríguez, D</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVO: Estudiar la posible relación entre las manifestaciones clínicas de la sarcoidosis y los polimorfismos del gen de laciclooxigenasa-2 (COX-2).MÉTODO: Estudio multicéntrico observacional transversal en el que participaron 7 hospitales de España. Se incluyeron pacientes diagnosticados de sarcoidosis según criterios internacionales. De cada caso se recogió edad, sexo, método diagnóstico, enzima convertidora de angiotensina, pruebas de función respiratoria, estadio radiológico y clínica del paciente en el momento del diagnóstico. Los hallazgos clínicos se agruparon en respiratorios y sistémicos. Los estudios genéticos se realizaron a partir del ADN obtenido de linfocitos de sangre periférica. El ADN se amplificó mediante PCR convencional y los polimorfismos fueron analizados por sondas de hibridación fluorescentes y curvas de disociación. Se determinaron4 variantes alélicas del gen de la COX-2: COX2.5909T&gt;G,COX2.8473T&gt;C, COX2.926G&gt;C y COX2.3050G&gt;C. RESULTADOS: La muestra se compuso de 131 casos de sarcoidosis (63 hombres; edad: 47 ± 15 años), todos con diagnóstico histológico menos 5 casos. El polimorfismo COX2.3050G&gt;C en homocigosis resultó estar significativamente presente entre los pacientes con manifestaciones sistémicas frente al resto de pacientes (4,6% vs 0%;p=0,045). La presencia de manifestaciones sistémicas de la enfermedad estuvo significativamente asociada a los pacientes portadores del alelo C de dicho polimorfismo (34,4% vs. 18,6%; p=0,031; OR:2,3; IC 95%: 1,03-5,12). El resto de polimorfismos estudiados no estuvieron relacionados con la expresión clínica de la enfermedad. CONCLUSIÓN: La presencia de manifestaciones sistémicas parece estar relacionada con los portadores del alelo C del polimorfismoCOX2.3050G&gt;C de la COX-2 (AU)</dc:description>
<dc:source>Neumosur (Sevilla);20(3): 140-145, jul.-sept. 2008. tab</dc:source>
<dc:identifier>ibc-84504</dc:identifier>
<dc:title xml:lang="es">Importancia de los polimorfismos de la ciclooxigenasa-2 en la presentación clínica de la sarcoidosis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d31059^s22033</dc:subject>
<dc:subject>^d485</dc:subject>
<dc:subject>^d50295</dc:subject>
<dc:subject>^d11547</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50591^s22033</dc:subject>
<dc:type>article</dc:type>
<dc:date>200809</dc:date>
</metadata>
</record>
</ibecs-document>
